Effects of pregnancy and contraception on lamotrigine disposition: New insights through analysis of lamotrigine metabolites Inger Öhman, Gerhard Luef, Torbjörn Tomson Seizure - European Journal of Epilepsy Volume 17, Issue 2, Pages 199-202 (March 2008) DOI: 10.1016/j.seizure.2007.11.017 Copyright © 2007 British Epilepsy Association Terms and Conditions
Figure 1 Dose/lamotrigine plasma concentration ratios in 20 non-users of oral contraceptives (controls), 12 users of intrauterine contraception devices containing progestin (CIUD), and 31 users of combined oral contraceptives (COC). Seizure - European Journal of Epilepsy 2008 17, 199-202DOI: (10.1016/j.seizure.2007.11.017) Copyright © 2007 British Epilepsy Association Terms and Conditions
Figure 2 Lamotrigine 2-N-glucuronide/lamotrigine plasma concentration ratios in 20 non users of oral contraceptives (controls), 12 users of intrauterine contraception devices containing progestin (CIUD), and 31 users of combined oral contraceptives (COC). Seizure - European Journal of Epilepsy 2008 17, 199-202DOI: (10.1016/j.seizure.2007.11.017) Copyright © 2007 British Epilepsy Association Terms and Conditions
Figure 3 Lamotrigine 2-N-glucuronide/lamotrigine plasma concentration ratio at different stages of pregnancy and up to three months postpartum in eight women treated with lamotrigine during pregnancy. Seizure - European Journal of Epilepsy 2008 17, 199-202DOI: (10.1016/j.seizure.2007.11.017) Copyright © 2007 British Epilepsy Association Terms and Conditions
Figure 4 Lamotrigine 2-N-glucuronide/lamotrigine urine concentration ratio at different stages of pregnancy and up to three months postpartum in eight women treated with lamotrigine during pregnancy. Seizure - European Journal of Epilepsy 2008 17, 199-202DOI: (10.1016/j.seizure.2007.11.017) Copyright © 2007 British Epilepsy Association Terms and Conditions